<DOC>
	<DOCNO>NCT00003695</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy surgery may kill tumor cell . It yet know whether chemotherapy plus surgery effective chemotherapy alone treat patient stage II stage III ovarian cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy without surgery treating patient stage II stage III ovarian cancer .</brief_summary>
	<brief_title>Chemotherapy With Without Surgery Treating Patients With Stage II Stage III Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine impact interval debulking surgery , term survival , disease-free survival , quality life , patient newly diagnose stage II III ovarian cancer residual macroscopic disease great 1 cm primary surgery . OUTLINE : This randomize study debulking surgery concurrent chemotherapy . Patients randomize receive chemotherapy alone ( arm I ) chemotherapy interval debulking surgery ( arm II ) . Arm I : Patients receive six course platinum-based chemotherapy interval 3 week . Arm II : Patients receive three course platinum-based chemotherapy interval 3 week . In absence disease progression , patient undergo interval debulking surgery approximately 21 day initiation third course chemotherapy . Surgery immediately follow three additional course platinum-based chemotherapy . Patients follow 6 month randomization , every 3 month remainder first 2 year , every 6 month follow 3 year , annually thereafter . Quality life assess prior randomization fourth course chemotherapy , follow-up visit 6 month 1 , 2 , 3 year . PROJECTED ACCRUAL : There 1,000 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose stage II III ovarian epithelial cancer Must plan receive platinumbased chemotherapy Must fit interval debulking surgery Residual macroscopic disease long dimension large tumor mass great 1 cm diameter document primary surgery postoperatively image PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No concurrent prior malignancy likely interfere protocol treatment comparison PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
</DOC>